Entradas Por :

Angel Alberich-Bayarri

Quibim Team

We are Hiring! Do you want to be a Quibimer?

We are excited to announce that we are seeking an Engineer to join our fantastic team in Valencia.

What do we need?

  • Enginner with 1-2 years of experience in the field of software development and medical imaging (biomedical, Computing, Electronics)
  • Experience as Java Developer
  • Experience with SQL databases
  • Experience in web development based on API-REST
  • Experience with GIT version control
  • Experience in application deployment with Apache Tomcat
  • Fluent english

Our ideal candidate’ Skills & Experience…

  • Experience with Spring or Jersey frames
  • Experience in integrating external APIs
  • Experience with the dcm4che library
  • Test Driven Development Experience (TDD / BDD)
  • Experience with the DICOM and HL7 standards
  • Experience in integration with PACS and RIS systems
  • Experience in developing CLI applications

What is a plus?

  • Experience with the C ++, Python or NodeJS languages
  • Experience as a FrontEnd
  • Experience with NoSQL databases
  • Experience with Microsoft Azure

If you are proactive, dynamic and forward thinking profile Apply Here

 

LA FUNDACIÓN IVI Y QUIBIM FIRMAN UN ACUERDO PARA INVESTIGAR EN IMAGEN MÉDICA Y REPRODUCCIÓN

La empresa QUIBIM S.L y la Fundación IVI han firmado un acuerdo de colaboración para el desarrollo de un proyecto científico en el ámbito de las enfermedades ginecológicas y/o reproductivas.

El proyecto está coordinado por el Profesor José Remohí, Presidente y Fundador de IVI, como Investigador Responsable, y por el Dr. Ángel Alberich, como fundador y director de QUIBIM SL, empresa spin-off del Instituto de Investigación Sanitaria La Fe dedicada al análisis avanzado de imágenes médicas.

Este acuerdo tiene como objetivo utilizar la tecnología de detección basada en algoritmos computacionales de imagen médica desarrollados por QUIBIM para la evaluación de la tasa de éxito en la donación de óvulos. El principal objetivo del proyecto es la aplicación de biomarcadores de imagen extraídos a partir de imágenes ecográficas para caracterizar la receptividad endometrial, ya que según la experiencia de los miembros del acuerdo el estado de esta membrana es un factor clave en la reproducción humana y fundamental en el tratamiento de donación de óvulos.

En el caso de pacientes sometidas a técnicas de reproducción asistida es preciso establecer y caracterizar los factores que contribuyen a aumentar la tasa de éxito en la implantación del embrión en el endometrio, para disponer de criterios objetivos sobre la posibilidad de embarazo.

El proyecto desarrollado por las dos empresas valencianas se hace con la finalidad de esclarecer unos métodos de diagnóstico y pronóstico en el área ginecológica y de la reproducción asistida.

Ángel Alberich Bayarri, ha destacado que “este acuerdo nos permite avanzar en un terreno hasta ahora desconocido en la medicina reproductiva como es la extracción de biomarcadores de imagen a partir de imágenes ginecológicas con la filosofía point-of-care, es decir, en la propia consulta. Con este proyecto buscamos biomarcadores pronósticos, y sus resultados pueden supones un cambio de paradigma en el manejo de las imágenes ginecológicas en la práctica clínica”.

Por su parte el Profesor Remohí ha asegurado que “para IVI la investigación siempre ha formado parte de la base de nuestra empresa. Es uno de nuestros pilares y este convenio nos va a permitir seguir trabajando en un proyecto científico en el ámbito de las enfermedades ginecológicas y reproductivas”.

Sobre QUIBIM

QUIBIM es una empresa biotecnológica de análisis avanzado de imágenes médicas, fue una de las start-ups valencianas seleccionadas en la 3ª edición del programa Lanzadera, actual Spin-off del programa Biopolo La Fe del Instituto de Investigación Sanitaria La Fe y que recientemente he cerrado una ronda de inversión para impulsar su crecimiento. El modelo de negocio de QUIBIM (Quantitative Imaging Biomarkers in Medicine) se basa en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear mediante técnicas originales y avanzadas de procesamiento computacional.

Sobre FIVI

La Fundación IVI, tiene como objetivo fundamental la Investigación básica y aplicada, la Docencia y la Responsabilidad Social Corporativa en el campo de la Reproducción Humana. La Fundación IVI opera como entidad sin ánimo de lucro y con autonomía funcional, con la finalidad de prestar un servicio de carácter científico, docente y social desde su fundación en el año 1997.

La Fundación IVI vehiculiza la producción científica y docente del grupo IVI y cuenta con más de 600 personas con perfil docente e investigador.

quibim_imaging-biomarkers_funding round

QUIBIM cierra una ronda de inversión de 550.000€

La financiación permitirá a la empresa mejorar su plataforma de análisis de imágenes médicas y su comercialización

 

Valencia, 27 de diciembre de 2016. QUIBIM S.L, empresa biotecnológica de análisis avanzado de imágenes médicas, ha anunciado el cierre de su primera ronda de financiación por un valor de 550.000 euros de la mano de Tech Transfer UPV, AYCE Capital, Bioinfogate y los propios promotores de la compañía.

Se trata de la primera empresa de España en cerrar una ronda de inversión con un fondo de transferencia tecnológica asociado a una Universidad Pública: TechTransfer UPV, cuya finalidad es la creación y consolidación de empresas con elevado potencial de crecimiento, procedentes del ámbito investigador. Esta ronda de inversión permitirá a la empresa acelerar el desarrollo y comercialización del producto para seguir creciendo como compañía referente en la gestión y procesado de imagen médica en el ámbito hospitalario e industria farmacéutica,  promoviendo así, su consolidación nacional y expansión internacional.

Con sede en Valencia, la empresa, que es Spin-Off del Instituto de Investigación Sanitaria La Fe, fue fundada en 2012 e impulsada por Ángel Alberich-Bayarri y el Dr. Luis Martí Bonmatí tras una larga trayectoria de investigación y desarrollo. Ángel Alberich-Bayarri es Dr. Ingeniero Biomédico por la Universidad Politécnica de Valencia y es el CEO de QUIBIM. Luis Martí-Bonmatí es un radiólogo de reconocido prestigio internacional y es el Director del Área Clínica de Imagen Médica del Hospital Universitario y Politécnico La Fe de Valencia.

El modelo de negocio de QUIBIM (Quantitative Imaging Biomarkers in Medicine) se  basa  en  la  extracción  de  información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear mediante técnicas originales y avanzadas de procesamiento  computacional. Para Alberich-Bayarri, QUIBIM tiene por objetivo: “mejorar  los  procesos  de  diagnóstico  de  enfermedades  con  alta  incidencia y  evaluar  adecuadamente  los  cambios  que  producen  los tratamientos farmacológicos en el organismo, para  aportar  así,  diagnósticos  mucho  más certeros y precoces, complementando de manera cuantitativa y medible la valoración cualitativa que se realiza a partir del ojo del radiólogo en la Medicina actual”.

QUIBIM fue una de las start-ups valencianas seleccionadas en la 3ª edición del programa Lanzadera, promovido por el Presidente de Mercadona, Juan Roig. El programa Lanzadera permitió impulsar a la empresa con formación y asesoramiento, así como con una financiación aproximada de 200.000€.

La startup ha desarrollado una plataforma de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía , TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar avanzados algoritmos de análisis que incluyen metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos.

La compañía comercializa diferentes modelos de análisis para hospitales, empresas farmacéuticas y radiólogos. Para 2017 mantiene un presupuesto de ventas de 500.000€ de los cuales a fecha de hoy tiene ya comprometido el 30%.

Según afirma Ángel Alberich-Bayarri: “Estamos muy satisfechos con el cierre de esta ronda porque supone un gran impulso para nosotros, la financiación nos permitirá mejorar nuestra plataforma de análisis y su comercialización. Además, los inversores no aportan únicamente el capital, sino también su experiencia en el sector biotecnológico, lo que nos es de especial relevancia en esta fase de crecimiento”.

Por su parte, Pedro de Álava, director del Fondo Tech Transfer UPV, ha destacado que “la imagen médica está revolucionando la medicina al aportar soluciones personalizadas, precisas y predictivas del comportamiento de las enfermedades. Y el proyecto de QUIBIM reúne talento, disciplina técnica y escalabilidad, lo que genera un amplio valor para hospitales, empresas farmacéuticas y pacientes”.

El Dr. José Mateos, especialista en diagnóstico por imagen y director médico de Imagen Ensayos Clínicos S.L (IEC) empresa líder en la gestión de imagen en ensayos clínicos con más de 10 años de experiencia aportando valor a los estudios promocionados por los principales laboratorios farmacéuticos y CROs a nivel internacional, ha explicado “Durante los últimos 3 años estamos creciendo y consolidando nuestra posición a nivel local y nacional. La inversión actual de nuestra compañía en Quibim y las sinergias ya establecidas hace unos meses entre ambas empresas nos situarán como referentes indispensables en ensayos clínicos a nivel nacional e internacional”.

El Dr Jose Prous, Director Ejecutivo de BioInfoGate y cofundador del Prous Institute for Biomedical Research subrayó: “Los biomarcadores de imagen constituyen un elemento clave para optimizar el descubrimiento, desarrolllo y aplicación clínica de fármacos más eficaces y seguros. En la nueva era de la medicina de precisión, los innovadores métodos analíticos desarrollados por QUIBIM, permitirán optimizar el abordaje terapéutico de múltiples enfermedades.”

Sobre Tech Transfer UPV, f.c.r

Tech Transfer UPV es el primer fondo de transferencia de tecnología impulsado dentro del sistema universitario español que apuesta por proyectos de transferencia de tecnología y emprendimiento generados en la Universitat Politècnica de València para acompañarlos en su salida al mercado.

Tras este primer cierre de inversión, dispone de un patrimonio de 3,9 millones de euros. El Fondo está participado por 28 empresarios y profesionales valencianos y de Castellón de diferentes sectores que, además de invertir, participan como validadores de los proyectos. Entre ellos, el Instituto Valenciano de Finanzas, Caixa Popular Productos Citrosol, Air Nostrum, Grupo IVI, Multiscan, ACAL, Arca Telecom, S2 Grupo, Miarco, La Unión Alcoyana Seguros, Nero Family, Blast of partners, Tecnopaking, Vik Consultoría o Ca&CCA ingeniería.

Sobre AYCE Capital e Imagen en Ensayos Clínicos S.L.

AYCE Capital es una gestora friendly Business Angels de Barcelona que trabaja con proyectos de sectores muy distintos: servicios, healthcare, industrial, retail, cultura, agro-alimentario, TIC…

IEC es inversor en QUIBIM de la mano de AYCE Capital

Sobre Bioinfogate

 

BIOINFOGATE (www.bioinfogate.com) es una spin-off del Prous Institute for Biomedical Research (www.prousresearch.com) , con sede en Barcelona. La empresa ha sido creada con el objetivo de dinamizar la investigación en biomedicina y tecnologías médicas mediante el uso intensivo de metodologías de “Data Science” (big data) y bases de datos especializadas.

Las soluciones desarrolladas por el grupo Prous han sido utilizadas con éxito, durante los últimos 50 años, por científicos de todo el mundo en el descubrimiento de nuevos fármacos. Primero desde Prous Science (adquirida por Thomson Reuters en 2007) empresa líder mundial en el desarrollo de bases de datos (Integrity) y publicaciones de química médica (Drug of the Future) y posteriormente desde el Prous Institute for Biomedical Research mediante el desarrollo de sistemas expertos en predicción de seguridad y toxicidad de fármacos (Symmetry) y la invención de nuevas moléculas para el tratamiento de enfermedades neurodegenerativas, cáncer y diabetes.

Los productos del grupo Prous se utilizan diariamente en todas las  organizaciones relacionadas con las ciencias de la salud incluyendo industrias farmacéuticas y de biotecnología, centros de investigación públicas y privados y agencias reguladoras como la U.S. Food and Drug Adminstration (FDA).

Complementariamente a los desarrollos propios, Bioinfogate invierte en proyectos emergentes que se alinean con nuestro negocio principal en ciencias de la vida y análisis de datos.

quibim_imaging-biomarkers_funding round

QUIBIM closes a seed funding round of €550,000

The funding will allow the company to improve the platform for medical image analysis and work in marketing and sales strategy

 

Valencia, 27 December 2016. QUIBIM SL is a biotechnology company dedicated to advanced medical image analysis that has announced the closing of its first round of funding worth 550,000 euros shared by Tech Transfer UPV, AYCE Capital, and Bioinfogate, besides the own promoters of the company.

It is the first company in Spain to close an investment round with a technology transfer fund associated with a Public University: TechTransfer UPV, whose purpose is the creation and consolidation of companies with high potential for growth, from the research field. This round of investment will enable the company to accelerate the development and commercialization of the product to continue to grow as a leading company in the management and processing of medical images for hospitals and the pharmaceutical industry, thus promoting its national consolidation and international expansion.

Based in Valencia (SPAIN), the company, which is Spin-Off of the Institute of Health Research La Fe, was founded in 2012 and promoted by Angel Alberich-Bayarri and Dr. Luis Martí Bonmatí after a long history of research and development. Ángel Alberich-Bayarri is PhD in Biomedical Engineering from the Polytechnic University of Valencia and is the CEO of QUIBIM. Luis Martí-Bonmatí is an international Key Opinion Leader in Radiology and is the Director of the Clinical Area of ​​Medical Image of the Hospital Universitario y Politécnico La Fe in Valencia.

The business model of QUIBIM (Quantitative Imaging Biomarkers in Medicine) is based on the extraction of quantitative information of medical images in radiology and nuclear medicine through original and advanced computer processing techniques. For Alberich-Bayarri, QUIBIM aims to: “improve the diagnostic processes of diseases with high incidence and adequately evaluate the changes that produce the pharmacological treatments in the organism, to contribute to much more accurate and early diagnoses, complementing in a quantitative and measurable way the qualitative valuation that is performed from the eye of the radiologist in today Medicine”.

QUIBIM was one of the start-ups valencianas selected in the 3rd edition of the acceleration program, promoted by the President of Mercadona, Juan Roig. The program allowed to boost the company with training and mentoring, as well as with a funding of approximately € 200,000.

The startup has developed a platform for medical image analysis in the cloud, which can be installed in private versions for hospitals and pharmaceutical companies to develop clinical trials. By using X-ray images, Ecography, CT, MRI or PET scans, QUIBIM is able to apply advanced analysis algorithms including GPU-based (graphics processing units) processing, or Big Data and Machine Learning methodologies. The QUIBIM software allows to provide more information in the diagnoses and to be able to evaluate in an early way the response to the pharmacological treatments.

The company markets different analytical models for hospitals, pharmaceutical companies and radiologists. For 2017 maintains a sales budget of 500,000 € of which to date has already committed 30%.

According to Angel Alberich-Bayarri: “We are very satisfied with this funding round because it is a great boost for us, the financing will allow us to improve our analysis platform and its commercialization. In addition, investors do not only contribute capital, but also their experience in the biotechnology sector, which is of special relevance to us in this phase of growth”

Pedro de Álava, director of the Tech Transfer UPV Fund, stressed that “the medical images are revolutionizing medicine by providing personalized, accurate and predictive solutions to the behavior of diseases. And the QUIBIM project brings together talent, technical discipline and scalability, which generates a wide value for hospitals, pharmaceutical companies and patients.”

Dr. José Mateos, a specialist in image diagnosis and medical director of Imagen Ensayos Clínicos SL (IEC), a leading company in image management in clinical trials with more than 10 years of experience, adding value to the studies promoted by the main pharmaceutical laboratories and CROs at the international level, stated “During the last 3 years we are growing and consolidating our position at local and national level. The current investment of our company in Quibim and the synergies already established a few months ago between both companies will place us as indispensable references in clinical trials at national and international level.”

Dr Jose Prous, Executive Director of BioInfoGate and co-founder of the Prous Institute for Biomedical Research, emphasized: “Imaging biomarkers are a key element in optimizing the discovery, development and clinical application of more effective and safe drugs. In the new era of precision medicine, the innovative analytical methods developed by QUIBIM will allow optimizing the therapeutic approach to multiple diseases. “

About Tech Transfer UPV, fcr

Tech Transfer UPV is the first transfer fund of technology promoted within the Spanish university system that bets on projects of technology transfer and entrepreneurship generated at the Universitat Politècnica de València to accompany them on their way out to the market.

After this first investment closure, it has a net worth of 3.9 million euros. The Fund is represented by 28 Valencian and Castellón businessmen and professionals from different sectors who, in addition to investing, participate as validators of the projects. Among them, the Valencian Institute of Finance, Caixa Popular, Productos Citrosol, Air Nostrum, Grupo IVI, Multiscan, ACAL, Arca Telecom, S2 Group, Miarco, La Unión Alcoyana Seguros, Nero Family, Blast of partners, Tecnopaking, Vik Consulting or Ca & CCA engineering.

About AYCE Capital e Imagen en Ensayos Clínicos SL

AYCE Capital is a friendly business angels manager from Barcelona who works with projects from very different sectors: services, healthcare, industrial, retail, culture, agri-food, ICT …

IEC is an investor in QUIBIM by the hand of AYCE Capital

About Bioinfogate

BIOINFOGATE ( www.bioinfogate.com ) is a spin-off of Prous Institute for Biomedical Research ( www.prousresearch.com ), based in Barcelona. The company has been created with the aim of boosting research in biomedicine and medical technologies through the intensive use of “Big Data” methodologies and specialized databases.

The solutions developed by the Prous group have been used successfully over the last 50 years by scientists worldwide in the discovery of new drugs. First from Prous Science (acquired by Thomson Reuters in 2007), the world’s leading developer of Integrity and Drug of the Future publications, and later from the Prous Institute for Biomedical Research through the development of systems Experts in safety prediction and drug toxicity (Symmetry) and the invention of new molecules for the treatment of neurodegenerative diseases, cancer and diabetes.

The products of the Prous group are used daily in all organizations related to the health sciences including biotechnology and pharmaceutical industries, public and private research centers and regulatory agencies such as the US Food and Drug Adminstration (FDA).

In addition to our own developments, Bioinfogate invests in emerging projects that are aligned with our core business in life sciences and data analysis.

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

The satisfaction of bringing together the best experts in the world at home

Dr. Luis Martí-Bonmatí (QUIBIM co-founder and director of advisory board) and myself had been locally organising the joint congress of the European Society of Oncological Imaging (ESOI) and the European Society of Medical Imaging Informatics (EuSoMII) for approximately 1 year, and the event finally took place past October from 6th to 8th at our home. The Venue was our hospital: La Fe Polytechnics and University Hospital, where we develop our professional activity and where QUIBIM headquarters are placed, since QUIBIM is a spin-off Company of La Fe Health Research Institute, the institutional arm of the hospital to perform research.

The topic of the congress was “Imaging Informatics in Oncology” and it was the result of joining both Societies fields like Oncology and Medical Imaging Informatics from ESOI and EUSOMII, respectively. The congress program combined workshops with plenary sessions. The workshops covered different concrete areas like Response to treatment, Tumor Boards, 3D printing, and Imaging Informatics for clinicians and computer scientists. The complete program can be found here.

I had the opportunity to present on our stepwise development of Imaging Biomarkers process and the associated bottlenecks for validation. Here you can find the slides of the presentation.

Our group had a really active participation, either from the Biomedical Imaging Research Group (GIBI230) from our Hospital and from QUIBIM.

The main scientific presentations were:

  1. ProstateChecker, a tool for the multi-variate analysis of Prostate Cancer from T2, diffusion and perfusion MR sequences, by David García-Juan, post-processing biomedical engineer at QUIBIM
  2. Cloud architecture for Imaging Biomarkers analysis, by Rafael Hernández, CTO at QUIBIM
  3. Spatial registration on PET-CT scans and quantitative structured report for treatment response evaluation on lymphoma patients, by Fabio García-Castro, post-processing biomedical engineer at QUIBIM
  4. Web application for PI-RADS 2.0 Structured Reporting, by Enrique Ruiz-Martínez, CTO at GIBI230 group
  5. Business analytic, metric, key performance indicator. Automating the monitorization of performance indicators in Radiology departments, by Enrique Ruiz-Martinez, CTO at GIBI230 group
  6. Platform for the integration of Imaging Biomarkers in Radiology Departments, by Enrique Ruiz-Martinez, CTO at GIBI230 group
  7. Integration of Redmine as a tool to manage Clinical Trials in Radiology, by Amadeo Ten-Esteve, Clinical Trial Manager at GIBI230 group.
  8. Artificial intelligence techniques applied to medical imaging. Deep learning applied to automated chest X-ray screening, by Belén Fos-Guarinos, internship biomedical engineering student at GIBI230 group.
  9. Automatic vertebrae localization in pathological spine CT using Decision Forests, by Ana Jiménez Pastor, internship telecommunications engineering student at QUIBIM.
  10. Automated segmentation of muscle using Neural Networks, by Sara Rocher, internship biomedical engineering student at GIBI230 group.
  11. Automatic classification of intensity-vs-time curves in breast DCE-MRI by K-means clustering and Dynamic Time Warping curve matching, by Fabio García-Castro, post-processing biomedical engineer at QUIBIM

In the meantime, the QUIBIM stand was boiling! With several experts interested…

QUIBIM CEO, Angel Alberich-Bayarri explaining QUIBIM advantages to interested attendees to EUSOMII - ESOI congress

QUIBIM CEO, Angel Alberich-Bayarri explaining QUIBIM advantages to interested attendees to EUSOMII – ESOI congress

Besides the opportunity to present the work of our group, we had some remarkable visits to our headquarters, like the visit of Dr. Regina Beets-Tan group together with Dr. Erik Ranschaert (see photo).

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

Industry also visited us, in this case it was Agfa Healthcare. The Global Senior Solution Manager, Mr. Chris Townend and the National Sales Manager, José Vicente Puig visited our headquarters and attended the demo of our solution.

Visit of José Vicente Puig (National Sales Manager at Agfa Healthcare) and Chris Townend (Global Senior Solution Manager at Agfa Healthcare)

Visit of José Vicente Puig (National Sales Manager at Agfa Healthcare) and Chris Townend (Global Senior Solution Manager at Agfa Healthcare)

 

The last day we were lucky to have Regina Beets-Tan and Sergey Mozorov, new presidents of ESOI and EUSOMII, respectively, at our headquarters.

 

Visit of Sergey Morozov and Regina Beets-Tan. Photo with QUIBIM founders

Visit of Sergey Morozov and Regina Beets-Tan. Photo with QUIBIM founders

 

The experience speaks by itself.

Katherine Wilisch new member of QUIBIM team

A new ‘quibimer’ in our team

We are pleased to announce the incorporation of Mrs. Katherine Wilisch Ramírez as a new member of our team. Katherine is graduate in Biotechnology and Master in Human Genetics by the University of Valencia has recently joined to the QUIBIM team as General Coordination and CEO support. Katherine has a remarkable experience in the field of innovation and technology transfer. She previously was coordinator at the VIT salud network and at the Spanish Association of Scientific Entrepreneurs. She has collaborated in the organisation of more than 10 events related to health, technology and innovation. We welcome Katherine in our team and we wish her a brilliant future in QUIBIM. Enjoy this new experience of your life joining our great team and thank you for becoming a ‘quibimer’.

Katherine Wilisch new member of QUIBIM team

Katherine Wilisch new member of QUIBIM team

Our experience at BIO 2016 and USA tour

We were delighted to be present at past BIO conference in San Francisco (Moscone Center), from 6th to 9th of June, with a booth in the Spanish pavillion. Our presence was due to the incorporation of QUIBIM in the ICEX next program, the Spanish program that assists SME’s in their internationalization.

I can now confirm that the meeting covered my expectations and I agree with the definition in their website: The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. This event covers a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

QUIBIM stand at BIO convention in Spain Pavillion and its CEO, Angel Alberich-BayarriQUIBIM stand at BIO convention in Spain Pavillion and its CEO, Angel Alberich-Bayarri

The attendees were also variate:

  • One-third of BIO attendees come from outside the U.S.
  • 2,500+ CEO’s from leading biotech companies
  • More than 70% of attendees are either Managers, Directors, C-Level or Executive Management.
  • All company sizes: 33% of attendees are from companies with more than 500 employees and 40% are from companies with fewer than 50 employees.

Our first event in the congress was the session “Spain Kicks off 2016 BIO International Convention” in a charming venue: The Ferry Building. A session were we were able to learn from leading experts on how to select the appropriate path, develop and execute our strategy successfully, as well as best practices and what we need to understand in any approach. High level executives from TTS Global Initiative, Breakout Labs, CytomX, GeronIRB Barcelona, pH PharmaRoche, Stanford University and the Thiel Foundation participated in the panel.

In the BIO convention, we had a total of 23 one-to-one partnering meetings organised. The meetings were very well organised and distributed and having the possibility of discussing 30 minutes with potential customers, providers or investors to explore further ways of collaboration justifies our presence in the congress. New business opportunities that are now being executed arose.

After BIO convention, we decided to spend a pair of days at Case Western Reserve Medical Center in Cleveland, visiting Dr. Pablo Ros, member of our advisory board and Chairman at the Department of Radiology in UH Case Medical Center. The purpose of the visit was to discover the biomedical engineering department and the projects that are being performed. Among the short meetings I shared with senior reserchers, I must highlight the meeting with Dr. Mark Griswold, the promoter of the MRI fingerprinting technique.

In summary, we will probably repeat our attendance at BIO conference due to the success of networking.

SMEInstrument

QUIBIM awarded with Phase I of SME Instrument Program 2016 H2020 by the European Commission  

QUIBIM is one of the disruptive companies selected by the EU to be granted with the first round of Horizon 2020 SME Instrument Phase I Program 2016 under the call: “SMEInst-01-2016-2017: Open Disruptive Innovation Scheme”. A H2020 funding-call with a success rate of 10%.

The dedicated SME instrument supports close-to-market activities, with the aim to give a strong boost to breakthrough innovation. Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalization are the prime target.

The European Commission will support QUIBIM project either economically and with a coaching program, helping it grow and expand as an international core reference laboratory for image centralization and medical image processing.

QUIBIM team is really proud of being elected by the EU with its first submitted proposal and we are really grateful for this relevant acknowledgment. We are already working on phase I, exploring and assessing the commercial potential of our innovative medical imaging services.

QUIBIM ha sido seleccionada por la Comisión Europea para la Fase I del Programa Instrumento PYME 2016 del H2020

QUIBIM ha sido una de las empresas seleccionadas por la CE en la primera convocatoria de Fase I del Programa Instrumento PYME 2016 del H2020 bajo la llamada: “SMEInst-01-2016-2017: Open Disruptive Innovation Scheme”. Un Programa del H2020 con una tasa de éxito del 10%.

El Instrumento PYME es una inicitativa dedicada al apoyo de actividades cercanas a mercado con el objetivo de impulsar la innovación disruptiva. PYMEs altamente innovadoras, con una ambición comercial clara y alto potencial de crecimiento e internacionalización son las candidatas a ser subvencionadas por este Programa.

La Comisión Europea apoyará el proyecto QUIBIM tanto económicamente como con ‘coaching’ internacional, impulsando así el crecimiento y la expansion de la empresa como laboratorio internacional de referencia para la centralización y el procesamiento de imágenes médicas.

En el equipo QUIBIM estamos muy orgullosos de haber sido elegidos por la CE en nuestra primera propuesta presentada y agradecidos por este importante reconocimiento. Actualmente, nos encontramos ya trabajando en esta Fase I, inmersos en la exploración y la evaluación del potencial comercial de nuestros servicios disruptivos en imagen médica.

EUSOMII

Let’s meet at the ESOI and EuSoMII Annual Meeting 2016

ESOI and EuSoMII will organise this year’s annual meeting jointly. The meeting will give imaging doctors the opportunity to understand the importance of informatics for oncologic imaging, in both clinical practice and research. It will also give insight on how information technology may contribute to enhance the multidisciplinary management of cancer patients and improve communication. A comprehensive series of workshops will be offered to participants, tailored for both clinicians and computer scientists. These courses will give the unique opportunity to discuss clinical cases in a multidisciplinary setting, train on specialized software and test structured reporting solutions.

The meeting, co-organized by QUIBIM founders, will take place in beautiful Valencia, a culturally rich and diversified city, an open-air museum overlooking the Mediterranean Sea.
We look forward to welcoming you in Valencia!

Congress Registration:
Click here to secure your place for the ESOI/EuSoMII Congress.

Congress Venue
Hospital La Fe
Avinguda de Fernando Abril Martorell, nº 106
46026, Valencia
Spain

Congress Programme
Kindly find the detailed preliminary programme on the ESOI website.

 

 

South Summit

Quibim has been chosen as a finalist for the startup competition of the South Summit 2016

Spain’s Startup-South Summit has visited the city of Valencia in order to find the most innovative and disruptive projects of the region. The aim of the meeting was to invite the startup community to participate in the Startup Competition of the new South Summit 2016 edition, an international meeting that will bring together the stakeholders with the most potential of the entrepreneurial ecosystem in Madrid from 5 to 7 October.

The Valencian Startup Competition took place in the ‘Marina de Empresas’ of Valencia, an initiative from the influential Spanish businessman Juan Roig, that supports the full cycle of entrepreneurship in the Mediterranean.

Thanks to this event we have had the opportunity to present the QUIBIM project to leading personalities of the national entrepreneurial ecosystem.

Between the 8 finalists (Beroomers, Cronoshare, Kerionics, Languing, MyTripCar, Quibim, Relendo and Rotary), QUIBIM was declared the winner and will go directly to the South Summit 2016.

South Summit is looking for the 100 most disruptive Startups from any industry and anywhere in the World, with the aim of building a global community and platform designed to bring Startups, Investors and Innovative corporations together.